EndoBarrier Improves Diabetes and Weight Loss: Ann Surg | July 2026

Introduction:

Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed device that temporarily excludes the proximal small intestine, aiming to improve glucose metabolism through both weight-dependent and weight-independent mechanisms.

Why was this study needed?:

. Many patients with obesity and uncontrolled T2DM do not achieve adequate control with medications and lifestyle modification.

. Bariatric surgery is highly effective but is not suitable or acceptable for all patients.

. Evidence from large randomized sham-controlled trials evaluating the EndoBarrier device has been limited.

. The balance between metabolic benefits and device-related safety required confirmation before wider adoption.

Results:

In this multicenter double-blind randomized sham-controlled trial, the EndoBarrier significantly improved glycemic control compared with sham treatment, with greater reductions in HbA1c and significantly higher rates of achieving target glycemic control. Patients receiving the device also experienced substantially greater weight loss and were more likely to achieve clinically meaningful weight reduction. Although device-related serious adverse events occurred, including gastrointestinal bleeding, intolerance, and hepatic abscess, the overall safety profile met the predefined study criteria and was considered acceptable with appropriate monitoring.

Clinical Impact:

The EndoBarrier offers an effective minimally invasive metabolic intervention for patients with obesity and poorly controlled T2DM who are not candidates for or decline bariatric surgery. While its metabolic benefits are clinically meaningful, careful patient selection and close surveillance are essential because of device-related complications, particularly hepatic abscess. The device may serve as an important bridge between pharmacotherapy and surgery in specialized centers.

Bottom Line:

The EndoBarrier significantly improved glycemic control and weight loss compared with sham treatment, supporting its role as an effective endoscopic metabolic therapy for selected patients with obesity and poorly controlled type 2 diabetes, provided appropriate safety monitoring is ensured.